Rani Therapeutics announces new preclinical PK data on GLP-1

Rani Therapeutics announced new pharmacokinetic, PK, data from a preclinical study evaluating a GLP-1, GIP and glucagon receptors incretin triagonist with a delivery method mimicking the RaniPill route of administration. A previous study with this incretin triagonist delivered transenterically demonstrated pharmacodynamic effects comparable to subcutaneous injection. Rani also previously completed a study demonstrating oral delivery of GLP-1 receptor agonist with high bioavailability via the RaniPill capsule. A single dose of drug delivered via either transenteric or SC routes elicited rapid decreases in body weight and serum lipids. Weight loss observed following transenteric delivery was 9.7 +/- 2.5 % versus 6.9 +/- 2.1 % following SC injection and is believed to be due to early satiety leading to reduced caloric intake. The drug was well tolerated in both groups with no serious adverse events, SAEs, observed or changes in safety markers examined.